CA2410965A1 - Method of stimulating hair growth - Google Patents

Method of stimulating hair growth Download PDF

Info

Publication number
CA2410965A1
CA2410965A1 CA002410965A CA2410965A CA2410965A1 CA 2410965 A1 CA2410965 A1 CA 2410965A1 CA 002410965 A CA002410965 A CA 002410965A CA 2410965 A CA2410965 A CA 2410965A CA 2410965 A1 CA2410965 A1 CA 2410965A1
Authority
CA
Canada
Prior art keywords
matrix
amino acids
polar amino
arginine
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002410965A
Other languages
French (fr)
Other versions
CA2410965C (en
Inventor
Anton-Lewis Usala
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Encelle Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2410965A1 publication Critical patent/CA2410965A1/en
Application granted granted Critical
Publication of CA2410965C publication Critical patent/CA2410965C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/042—Gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A61K38/014—Hydrolysed proteins; Derivatives thereof from animals from connective tissue peptides, e.g. gelatin, collagen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0052—Mixtures of macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/008—Hydrogels or hydrocolloids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/52—Hydrogels or hydrocolloids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/18—Materials or treatment for tissue regeneration for hair reconstruction

Abstract

The invention provides a method of stimulating hair growth, comprising administering a therapeutic amount of a hydrogel matrix to an intradermal or subdermal site where hair growth is desired, the matrix composition comprising gelatin, such as denatured collagen, and a long chain carbohydrate, such as dextran. The matrix may further include polar amino acids, nitric oxide inhibitors and super oxide inhibitors. Injection is a preferred method of administration.

Claims (29)

1. A method of stimulating hair growth, comprising administering a therapeutic amount of a hydrogel matrix to an intradermal or subdermal site where hair growth is desired, the matrix composition comprising gelatin and a long chain carbohydrate.
2. The method of Claim 1, wherein the matrix comprises about 0.01 to about 40 mM gelatin.
3. The method of Claim 1, wherein the gelatin comprises denatured collagen.
4. The method of Claim 1, wherein the long chain carbohydrate comprises dextran.
5. The method of Claim 4, wherein the matrix comprises about 0.01 to about mM dextran.
6. The method of Claim 1, wherein the long chain carbohydrate has a molecular weight of about 20,000 to about 1,000,000 Daltons.
7. The method of Claim 1, wherein the matrix further comprises an effective amount of polar amino acids selected from the group consisting of arginine, lysine, histidine, glutamic acid, and aspartic acid.
8. The method of Claim 7, wherein the effective amount of polar amino acids comprises about 3 to about 150 mM of polar amino acids.
9. The method of Claim 7, wherein the effective amount of polar amino acids comprises about 10 to about 65 mM of polar amino acids.
10. The method of Claim 7, wherein the polar amino acids are selected from the group consisting of arginine, glutamic acid, lysine and mixtures thereof.
11. The method according to claim 10, wherein the matrix comprises:
about 2 to about 60 mM of L-glutamic acid;
about 0.5 to about 30 mM of L-lysine; and about 1 to about 40 mM of arginine.
12. The method of Claim 11, wherein the matrix comprises:
about 5 to about 40 mM of L-glutamic acid;
about 1 to about 15 mM of L-lysine; and about 1 to about 30 mM of arginine.
13. The method according to claim 10, wherein the effective amount of polar amino acids comprises about 2 to about 60 mM of L-glutamic acid.
14. The method according to claim 10, wherein the effective amount of polar amino acids comprises about 1 to about 40 mM of arginine.
15. The method of Claim 10, wherein the effective amount of polar amino acids comprises about 0.5 to about 30 mM of L-lysine.
16. The method of Claim 1, wherein the matrix further comprises at least one nitric oxide inhibitor.
17. The method of Claim 16, wherein the nitric oxide inhibitor is selected from the group consisting of L-cysteine, L-arginine analogues, cystine, heparin, and mixtures thereof.
18. The method of Claim 16, wherein the nitric oxide inhibitor is present in an amount of about 5 to about 1000 µM.
19. The method of Claim 16, wherein the nitric oxide inhibitor is present in an amount of about 20 to about 200 µM.
20. The method of Claim 1, wherein the matrix further comprises about 5 to about 500 µM of L-cysteine.
21. The method of Claim 20, wherein the matrix comprises about 15 to about 25 µM of L-cysteine.
22. The method of Claim 1, wherein the matrix further comprises about 5 to about 500 µM of an L-arginine analogue.
23. The method of Claim 22, wherein the L-arginine analogue comprises aminoguanidine.
24. The method of Claim 22, wherein the matrix comprises about 15 to about
25 µM of an L-arginine analogue.

25. The method of Claim 1, wherein the matrix further comprises a superoxide inhibitor.
26. The method of Claim 25, wherein the superoxide inhibitor comprises EDTA or a salt thereof.
27. The method of Claim 25, wherein the superoxide inhibitor is present in an amount of about 1 to about 8 mM.
28. The method of claim 1, wherein the gelatin comprises denatured collagen and the long chain carbohydrate comprises dextran.
29. The method of Claim 1, wherein said administering step comprises injecting the matrix into one or more intradermal or subdermal locations.
CA2410965A 2000-05-31 2001-05-30 Method of stimulating hair growth Expired - Fee Related CA2410965C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20811600P 2000-05-31 2000-05-31
US60/208,116 2000-05-31
PCT/US2001/017386 WO2001091773A2 (en) 2000-05-31 2001-05-30 Method of stimulating hair growth

Publications (2)

Publication Number Publication Date
CA2410965A1 true CA2410965A1 (en) 2001-12-06
CA2410965C CA2410965C (en) 2010-09-14

Family

ID=22773242

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2410968A Expired - Fee Related CA2410968C (en) 2000-05-31 2001-05-30 Method of treating chronic ulcers
CA2410965A Expired - Fee Related CA2410965C (en) 2000-05-31 2001-05-30 Method of stimulating hair growth

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA2410968A Expired - Fee Related CA2410968C (en) 2000-05-31 2001-05-30 Method of treating chronic ulcers

Country Status (8)

Country Link
US (2) US7700660B2 (en)
EP (1) EP1289537B1 (en)
AT (1) ATE311192T1 (en)
AU (3) AU2001263495B2 (en)
CA (2) CA2410968C (en)
DE (1) DE60115433T2 (en)
NZ (1) NZ523461A (en)
WO (2) WO2001091774A2 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7828749B2 (en) * 1996-05-17 2010-11-09 Roche Diagnostics Operations, Inc. Blood and interstitial fluid sampling device
WO2004082459A2 (en) * 2003-03-13 2004-09-30 Burgess Cheryl M Methods of administering a material into a patient for dermal enhancement
JP2005269232A (en) * 2004-03-18 2005-09-29 Renesas Technology Corp Frequency mixer
US8829051B2 (en) * 2004-05-24 2014-09-09 Geoffrey C. GURTNER Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or acute increases of free fatty acid flux
WO2009137074A1 (en) * 2008-05-06 2009-11-12 Indigene Pharmaceuticals, Inc. Compositions and methods for treating diabetic ulcers
US10098857B2 (en) 2008-10-10 2018-10-16 The Board Of Trustees Of The Leland Stanford Junior University Topical and transdermal delivery of HIF-1 modulators to prevent and treat chronic wounds
EP2236617A1 (en) * 2009-03-31 2010-10-06 Leukocare Ag Methods of terminal sterilization of biofunctional compositions
AU2010314994B2 (en) 2009-11-09 2016-10-06 Spotlight Technology Partners Llc Fragmented hydrogels
WO2011057131A1 (en) 2009-11-09 2011-05-12 Spotlight Technology Partners Llc Polysaccharide based hydrogels
WO2013067195A1 (en) 2011-11-02 2013-05-10 Halscion, Inc. Methods and compositions for wound treatment
WO2013096650A2 (en) 2011-12-23 2013-06-27 Pioneer Surgical Technology Continuous matrix with osteoconductive particles dispersed therein, method of forming thereof, and method of regenerating bone therewith
US11931325B2 (en) * 2015-10-20 2024-03-19 Eaderm Co., Ltd. Hair-growth promoting composition and usage thereof
KR102085404B1 (en) * 2016-08-31 2020-03-05 주식회사 에스엔비아 Composition for treatment of partial obesity and microneedle comprising the composition
EP3558243B1 (en) 2016-12-21 2022-10-05 Unilever IP Holdings B.V. Personal care compositions comprising poorly soluble compounds
EA038885B1 (en) 2016-12-21 2021-11-02 ЮНИЛЕВЕР АйПи ХОЛДИНГС Б.В. Topical skin lightening additive and composition with amino acids and nicotinamide compounds
CA3046037A1 (en) 2016-12-21 2018-06-28 Unilever Plc Personal care compositions with glutathione precursor comprising 4-substituted resorcinols and amino acids
JP7082623B2 (en) 2016-12-21 2022-06-08 ユニリーバー・アイピー・ホールディングス・ベスローテン・ヴェンノーツハップ Composition for personal care with cystine
WO2019055490A1 (en) 2017-09-14 2019-03-21 The Board Of Trustees Of The Leland Stanford Junior University Conditioning irradiated tissue for fat graft retention
JP2021526127A (en) 2018-05-23 2021-09-30 ユニリーバー・ナームローゼ・ベンノートシヤープ Nanoemulsion and its manufacturing method
CN113679846B (en) * 2021-08-31 2023-05-09 佛山市第一人民医院（中山大学附属佛山医院） Hair regenerating agent and preparation method and application thereof

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4198479A (en) 1979-03-30 1980-04-15 Merck & Co., Inc. Replacement of animal serum proteins by human albumin for growth and interferon production by Namalva cells
US4520821A (en) 1982-04-30 1985-06-04 The Regents Of The University Of California Growing of long-term biological tissue correction structures in vivo
US4657866A (en) * 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US5852009A (en) 1984-03-19 1998-12-22 The Rockefeller University Compositions, including pharmaceutical compositions, for inhibiting the advanced glycosylation of proteins, and therapeutic methods based thereon
US4665192A (en) * 1984-03-19 1987-05-12 The Rockefeller University 2-(2-furoyl)-4(5)-2(furanyl)-1H-imidazole
US4868121A (en) 1985-02-07 1989-09-19 Mcdonnell Douglas Corporation Islet isolation process
NO166836C (en) * 1985-03-14 1991-09-11 Univ California PROCEDURE FOR TREATMENT OF AN ORGAN TRANSPLANT.
AU589438B2 (en) 1985-08-26 1989-10-12 Hana Biologics, Inc. Transplantable artificial tissue and process
US4902295A (en) 1985-08-26 1990-02-20 Hana Biologics, Inc. Transplantable artificial tissue
GB8604497D0 (en) * 1986-02-24 1986-04-03 Connaught Lab Separation of islets of langerhans
FR2600076A1 (en) * 1986-06-12 1987-12-18 Fond Ctre Nal Transfusion CULTURE MEDIUM COMPRISING HUMAN ALBUMIN, PROCESS FOR PREPARING A PRODUCT INJECTABLE THEREFROM, PRODUCT OBTAINED AND USE THEREOF, COMPOSITION OBTAINED
US5079160A (en) * 1987-06-08 1992-01-07 Lacy Paul E Method to isolate clusters of cell subtypes from organs
US5457093A (en) 1987-09-18 1995-10-10 Ethicon, Inc. Gel formulations containing growth factors
AU632273B2 (en) 1988-03-09 1992-12-24 Terumo Kabushiki Kaisha Medical material permitting cells to enter thereinto and artificial skin
US4950483A (en) * 1988-06-30 1990-08-21 Collagen Corporation Collagen wound healing matrices and process for their production
EP0363125A3 (en) 1988-10-03 1990-08-16 Hana Biologics Inc. Proliferated pancreatic endocrine cell product and process
US4957902A (en) 1988-12-20 1990-09-18 Board Of Regents, The University Of Texas System Peptide inhibitors of wound contraction
US5059588A (en) * 1989-10-13 1991-10-22 Procyte Corporation, Incorporated Methods and compositions for healing bone using gly his lys: copper
WO1991009119A1 (en) 1989-12-13 1991-06-27 Trancel Corporation Improved alginate microcapsules, methods of making and using same
US5645591A (en) * 1990-05-29 1997-07-08 Stryker Corporation Synthetic bone matrix
US5336616A (en) 1990-09-12 1994-08-09 Lifecell Corporation Method for processing and preserving collagen-based tissues for transplantation
US5192312A (en) * 1991-03-05 1993-03-09 Colorado State University Research Foundation Treated tissue for implantation and methods of treatment and use
DK0585368T3 (en) 1991-04-25 1998-03-16 Univ Brown Res Found Implantable biocompatible immuno-insulating vehicle for delivery of selected therapeutic products
US5605938A (en) 1991-05-31 1997-02-25 Gliatech, Inc. Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate
CA2071137A1 (en) 1991-07-10 1993-01-11 Clarence C. Lee Composition and method for revitalizing scar tissue
US5591709A (en) 1991-08-30 1997-01-07 Life Medical Sciences, Inc. Compositions and methods for treating wounds
WO1994015589A1 (en) 1992-12-30 1994-07-21 Clover Consolidated, Limited Cytoprotective, biocompatible, retrievable macrocapsule containment systems for biologically active materials
US5358969A (en) * 1991-12-16 1994-10-25 Washington University Method of inhibiting nitric oxide formation
US5246971A (en) 1991-12-16 1993-09-21 Washington University Method of inhibiting nitric oxide formation
US5824331A (en) * 1992-02-24 1998-10-20 Encelle, Inc. Bioartificial devices and cellular matrices therefor
US5834005A (en) 1992-02-24 1998-11-10 Encelle, Inc. Bioartificial devices and cellular matrices therefor
CA2109065C (en) 1992-02-24 2004-03-30 Anton-Lewis Usala Bioartificial endocrine device
US5830492A (en) 1992-02-24 1998-11-03 Encelle, Inc. Bioartificial devices and cellular matrices therefor
US6231881B1 (en) * 1992-02-24 2001-05-15 Anton-Lewis Usala Medium and matrix for long-term proliferation of cells
AU3733293A (en) 1992-02-25 1993-09-13 Alteon Inc. Method and agents for promoting wound healing
EP0641196B1 (en) 1992-05-29 2001-08-22 Vivorx, Incorporated Microencapsulation of cells
EP0655910A4 (en) 1992-07-29 1996-02-28 Univ Washington Use of pouch for implantation of living cells.
US5262055A (en) 1992-10-19 1993-11-16 The University Of Utah Implantable and refillable biohybrid artificial pancreas
DE4431598C2 (en) 1993-03-03 1997-03-20 Michael Sittinger Process for producing an implant from cell cultures
DE69434626D1 (en) 1993-11-17 2006-04-20 Athena Neurosciences Inc TRANSPARENT LIQUID FOR THE ADMINISTRATION OF CAPTIVATED MEDICAMENTS
ATE408005T1 (en) 1994-01-13 2008-09-15 Rogosin Inst MACRO-ENCAPSULED SECRETORY CELLS
US5487899A (en) * 1994-01-31 1996-01-30 Jess Clarke & Sons, Inc. Wound healing
US5716404A (en) 1994-12-16 1998-02-10 Massachusetts Institute Of Technology Breast tissue engineering
US5840059A (en) * 1995-06-07 1998-11-24 Cardiogenesis Corporation Therapeutic and diagnostic agent delivery
CA2179341A1 (en) 1996-04-12 1997-10-13 Gregory S. Korbutt Methods for isolating, enriching and increasing the maturation of cells
CA2251129A1 (en) * 1996-05-03 1997-11-13 Innogenetics N.V. New medicaments containing gelatin cross-linked with oxidized polysaccharides
US5972332A (en) * 1997-04-16 1999-10-26 The Regents Of The University Of Michigan Wound treatment with keratinocytes on a solid support enclosed in a porous material
EP0986408B1 (en) * 1997-06-03 2005-05-11 Innogenetics N.V. New medicaments based on polymers composed of methacrylamide-modified gelatin
CN1283997A (en) * 1997-12-22 2001-02-14 人类基因组科学公司 Keratinocyte growth factor-2 formulations
CA2337051C (en) * 1998-07-10 2007-04-17 Encelle, Inc. Methods for increasing vascularization and promoting wound healing
US6372494B1 (en) * 1999-05-14 2002-04-16 Advanced Tissue Sciences, Inc. Methods of making conditioned cell culture medium compositions
US6046160A (en) * 1999-07-22 2000-04-04 Deroyal Industries, Inc. Composition and method for enhancing wound healing
US6491953B1 (en) * 2000-01-07 2002-12-10 Amcol International Corporation Controlled release compositions and method
US20020146439A1 (en) * 2000-03-31 2002-10-10 Delong Mitchell Anthony Compositions and methods for treating hair loss using oximyl and hydroxylamino prostaglandins

Also Published As

Publication number Publication date
DE60115433D1 (en) 2006-01-05
AU2001265151A1 (en) 2001-12-11
US20020077277A1 (en) 2002-06-20
US20020065222A1 (en) 2002-05-30
WO2001091773A3 (en) 2002-05-02
NZ523461A (en) 2004-11-26
WO2001091774A2 (en) 2001-12-06
EP1289537B1 (en) 2005-11-30
ATE311192T1 (en) 2005-12-15
CA2410968C (en) 2011-03-29
AU6349501A (en) 2001-12-11
CA2410968A1 (en) 2001-12-06
EP1289537A2 (en) 2003-03-12
US7700660B2 (en) 2010-04-20
WO2001091774A3 (en) 2002-05-02
DE60115433T2 (en) 2006-08-03
US6992062B2 (en) 2006-01-31
CA2410965C (en) 2010-09-14
AU2001263495B2 (en) 2005-06-02
WO2001091773A2 (en) 2001-12-06

Similar Documents

Publication Publication Date Title
CA2410965A1 (en) Method of stimulating hair growth
ATE326243T1 (en) METHODS TO IMPROVE VASCULARIZATION AND PROMOTE WOUND HEALING
EP1321516A3 (en) Hydrogel matrix for cellular tissue storage
ES2163444T3 (en) COMPOSITIONS AND METHODS FOR THE ORAL ADMINISTRATION OF PHARMACOS.
EE05472B1 (en) Use of fumaric acid amides as a medicine
ATE430165T1 (en) PEPTIDES WITH INTEGRIN BINDING MOTIVE AND TREATMENT METHODS FOR MUSCLE DISEASES
DE69736487D1 (en) PEPTIDE COMPOSITION WITH GROWTH FACTOR-SIMILAR ACTIVITY
CA2334941A1 (en) Tnf-derived peptides for use in treating oedema
WO2002058589A3 (en) Agents and methods for promoting bone growth
NO955067D0 (en) FVII / TF peptides
AU2002309121A1 (en) Amino-acid-based compositions, suitable in therapy for the healing and/or mending of wounds and lesions, in particular for application in the ophthalmic field
PT1296675E (en) COMPOSITIONS BASED ON AMINOACIDES SUITABLE FOR THE TREATMENT OF INSUFFICIENCIACARDIACA
CA2558985A1 (en) Erythropoietin liquid formulation
RU2002135669A (en) OLIGOPEPTIDES
EP1623723A3 (en) Stable gene formulations
WO2000033852B1 (en) Compound and method for degrading amino acids
CA2337051A1 (en) Methods for increasing vascularization and promoting wound healing
Baran Nail fragility and nail beautification
WO1998001474A3 (en) Derivatives of somatostatin, amino acids or oligopeptides and their combination useful for promoting body growth
IS3511A7 (en) Polypeptides produced by the biotechnology methods, their corresponding nucleic acids, and the use of the polypeptides as a vaccine against VHS virus in fish
RU2002107317A (en) New dipeptidyl peptidase IV effectors for topical application

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20200831